Thermo Fisher Scientific Inc.

NYSE:TMO

Medical - Diagnostics & Research

Healthcare
$692.74 +0.96%

+$4.45 today

Market cap
$256.67B
Beta
0.87
P/E (TTM)
25.3
EPS (TTM)
$18.44
Dividend yield
0.39%
52W Low $390.50High $643.99

Volume 1.99M

Average 2.23M

TMO EBITDA Margin

EBITDA as a percentage of revenue.

Thermo Fisher Scientific Inc.NYSE: TMO

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin narrows to 20.6%

EBITDA Margin was 20.6% in Q3 FY2026, down 4.8 pp from a year earlier. On a trailing-twelve-month basis it was 23.7%, down 2.2 pp year over year. Over 3 fiscal years it narrowed by 0.9 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 20 analysts of 30.4% for the fiscal year ending Dec 2026, up from 25.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
20.6%-3.6 pp QoQ
Last fiscal yearDec 2025
25.7%-1.8 pp YoY
LTMSep 2026
23.7%-2.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-4.8 pp+5.4 pp+10.2 pp
1 year-1.8 pp+4.7 pp+6.4 pp
3 years-0.9 pp+4.6 pp+5.4 pp
5 years+7.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
25.7%
Year-over-year change
-1.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How TMO compares with its peers on the latest reported figures

  • TMO's LTM Sep 2026 EBITDA Margin of 23.7% is the 7th highest of the 10 companies compared; the peer median is 26.8%.
  • Its year-over-year change of -2.2 pp is the 6th highest of 10, against a peer median of -1.6 pp.
  • Over three fiscal years its change of -0.9 pp compares with a peer median of -2.3 pp.
TMO Competitors Peer median
EBITDA Margin for TMO and competitors
Company Period LTM level YoY 3-year change
QGENQiagen N.V.LTM Jun 202633.5% -1.6 pp-2.1 pp
MTDMettler-Toledo International Inc.LTM Jun 202631.6% +0.0 pp-0.7 pp
DHRDanaher CorporationLTM Sep 202627.7% -0.6 pp-7.3 pp
AAgilent Technologies, Inc.LTM Jul 202627.6% +1.1 pp-1.4 pp
TECHBio-Techne CorporationLTM Sep 202626.8% +8.6 pp-11.9 pp
RVTYRevvity, Inc.LTM Jul 202626.3% -3.0 pp-8.9 pp
TMOThermo Fisher Scientific Inc.LTM Sep 202623.7% -2.2 pp-0.9 pp
WATWaters CorporationLTM Jul 202620.5% -14.2 pp-2.3 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202619.9% -6.2 pp+208.5 pp
BRKRBruker CorporationLTM Jun 20267.1% -4.6 pp-11.7 pp
Peer median (excluding TMO) 26.8%-1.6 pp-2.3 pp

Competitors are the stored peer set for TMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue39.21B44.92B42.86B42.88B44.56B
Cost of Revenue19.58B25.9B25.66B25.15B26.32B
Gross Profit19.63B19.01B17.19B17.73B18.24B
Gross Margin50.1%42.3%40.1%41.3%40.9%
Research & Development1.41B1.47B1.34B1.39B1.4B
Selling, General & Admin7.91B9.02B8.41B8.68B8.73B
Operating Expenses9.32B10.49B9.75B10.07B10.13B
Depreciation & Amortization2.59B3.38B3.41B3.11B2.78B
EBITDA11.97B11.94B11.2B11.8B11.47B
EBITDA Margin30.5%26.6%26.1%27.5%25.7%
Operating Income10.32B8.53B7.45B7.66B8.11B
Operating Margin26.3%19.0%17.4%17.9%18.2%
Interest Income43M272M879M1.08B993M
Interest Expense536M726M1.49B1.65B1.42B
Other Income / Expenses(1.48B)(862M)(1.21B)(667M)(842M)
Income Before Tax8.84B7.66B6.24B7B7.27B
Pre-Tax Margin22.5%17.1%14.6%16.3%16.3%
Income Tax Expense1.11B703M284M657M547M
Net Income7.73B6.95B6B6.34B6.74B
Net Margin19.7%15.5%14.0%14.8%15.1%
EPS (Basic)19.6117.7315.5316.5817.77
EPS (Diluted)19.4617.6415.4516.5317.74
Weighted Avg Shares394M392M386M382M376M
Weighted Avg Shares (Diluted)397M394M388M383M377M

Thermo Fisher Scientific Inc.

NYSE:TMO

Intrinsic Alpha fair value

Locked

Current Price

$692.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.